These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 27215089

  • 21. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
    Chow YP, Zainul Abidin N, Kow KS, Tho LM, Wong CL.
    PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
    [Abstract] [Full Text] [Related]

  • 22. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
    Zheng R, Shen Q, Mardekian S, Solomides C, Wang ZX, Evans NR.
    J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
    [Abstract] [Full Text] [Related]

  • 23. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
    Martín Martorell P, Huerta M, Compañ Quilis A, Abellán R, Seda E, Blesa S, Chaves FJ, Dualde Beltrán D, Roselló Keränen S, Franco J, Insa A.
    Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
    [Abstract] [Full Text] [Related]

  • 24. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
    Hinrichs JW, van Blokland WT, Moons MJ, Radersma RD, Radersma-van Loon JH, de Voijs CM, Rappel SB, Koudijs MJ, Besselink NJ, Willems SM, de Weger RA.
    Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
    [Abstract] [Full Text] [Related]

  • 25. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X, Huang F, Cao M, Chen X, Wang H, Jiang H, Yu Y, Shen M, Yang Y, Wang B, Liu T, Guo W.
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [Abstract] [Full Text] [Related]

  • 26. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
    Lim GHT, Balbi KJ, Poskitt B, Bennett P, Moore DA.
    Lung Cancer; 2022 Nov; 173():71-74. PubMed ID: 36156323
    [Abstract] [Full Text] [Related]

  • 27. Somatic mutations and immune checkpoint biomarkers.
    Parris BA, Shaw E, Pang B, Soong R, Fong K, Soo RA.
    Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
    [Abstract] [Full Text] [Related]

  • 28. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
    Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard N, Trédaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J, Larivé S, Foucher P, Duvert B, Vallee M, Le Calvez-Kelm F, McKay J, Missy P, Morin F, Zalcman G, Olivier M, Souquet PJ, BioCAST/IFCT-1002 investigators.
    Clin Cancer Res; 2014 Sep 01; 20(17):4613-24. PubMed ID: 25013125
    [Abstract] [Full Text] [Related]

  • 29. Next-Generation Sequencing (NGS) Methods Show Superior or Equivalent Performance to Non-NGS Methods on BRAF, EGFR, and KRAS Proficiency Testing Samples.
    Surrey LF, Oakley FD, Merker JD, Long TA, Vasalos P, Moncur JT, Kim AS.
    Arch Pathol Lab Med; 2019 Aug 01; 143(8):980-984. PubMed ID: 30865489
    [Abstract] [Full Text] [Related]

  • 30. Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
    Ma W, Brodie S, Agersborg S, Funari VA, Albitar M.
    Mol Diagn Ther; 2017 Oct 01; 21(5):571-579. PubMed ID: 28639239
    [Abstract] [Full Text] [Related]

  • 31. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
    Szpechcinski A, Moes-Sosnowska J, Skronska P, Lechowicz U, Pelc M, Szolkowska M, Rudzinski P, Wojda E, Maszkowska-Kopij K, Langfort R, Orlowski T, Sliwinski P, Polaczek M, Chorostowska-Wynimko J.
    Int J Mol Sci; 2024 Jul 19; 25(14):. PubMed ID: 39063150
    [Abstract] [Full Text] [Related]

  • 32. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, Suzuki K, Asamura H, Furuta K, Kohno T, Kushima R.
    Ann Oncol; 2014 Jan 19; 25(1):138-42. PubMed ID: 24297085
    [Abstract] [Full Text] [Related]

  • 33. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B, Wu S, Huang F, Shen M, Jiang H, Yu Y, Yu Q, Yang Y, Zhao Y, Zhou Y, Pan B, Liu T, Guo W.
    Clin Chem Lab Med; 2019 Sep 25; 57(10):1501-1510. PubMed ID: 31339850
    [Abstract] [Full Text] [Related]

  • 34. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.
    Xie F, Zheng X, Mao X, Zhao R, Ye J, Zhang Y, Sun J.
    Ann Thorac Surg; 2019 Jul 25; 108(1):219-226. PubMed ID: 30885850
    [Abstract] [Full Text] [Related]

  • 35. Comparison of Biocartis IDYLLA ™ cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes.
    Haiduk T, Brockmann M, Tillmann RL, Pieper M, Lüsebrink J, Schildgen V, Schildgen O.
    Exp Mol Pathol; 2021 Jun 25; 120():104634. PubMed ID: 33773991
    [Abstract] [Full Text] [Related]

  • 36. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M, Mahmoodzadeh H, Fazeli MS, Haddadi-Aghdam M, Teimoori-Toolabi L.
    Mol Cell Probes; 2022 Jun 25; 63():101807. PubMed ID: 35296442
    [Abstract] [Full Text] [Related]

  • 37. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T, Robinson C, Grieu-Iacopetta F, Millward M, Iacopetta B, Spagnolo D, Amanuel B.
    Pathology; 2018 Jun 25; 50(4):389-401. PubMed ID: 29752127
    [Abstract] [Full Text] [Related]

  • 38. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
    Dalal AA, Guerin A, Mutebi A, Culver KW.
    J Med Econ; 2018 Jul 25; 21(7):649-655. PubMed ID: 29516752
    [Abstract] [Full Text] [Related]

  • 39. Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.
    Cernomaz AT, Macovei II, Pavel I, Grigoriu C, Marinca M, Baty F, Peter S, Zonda R, Brutsche M, Grigoriu B.
    BMC Pulm Med; 2016 May 23; 16(1):88. PubMed ID: 27215400
    [Abstract] [Full Text] [Related]

  • 40. Clinical next-generation sequencing in patients with non-small cell lung cancer.
    Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R.
    Cancer; 2015 Feb 15; 121(4):631-9. PubMed ID: 25345567
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.